Potential strategies to combat the opioid crisis

References

• Ballantyne JC, Murinova N, Krashin DL. Opioid guidelines are a necessary response to the opioid crisis. Clin Pharmacol Ther. 2018;103:946–949.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016; 2016. (MMWR Recomm. Rep. 65(No. RR-1)), 49.
   Google Scholar
• Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and the likelihood of long term opioid use – United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017 March 17;66(10):265–269.
   PubMedGoogle Scholar
• Cheung, CW, Qiu Q, Choi SW, et al. Chronic opioid therapy for chronic non-cancer pain: a review and comparison of treatment guidelines. Pain Physician. 2014;17:401–414.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National vital statistics system: mortality data. 2015 [cited 2016 Mar 18]. Available from: http://www.cdc.gov/nchs/deaths.htm
   Google Scholar
• Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies—tackling the opioid overdose epidemic. N Engl J Med. 2014;370:2063–2066.
   PubMed Web of Science ®Google Scholar
• Tan PD, Barclay JS, Blackhall LJ. Do palliative care clinics screen for substance abuse and diversion? Results of a national survey. J Palliat Med. 2015;18(9):752–757.
   PubMed Web of Science ®Google Scholar
• Becker WC, Sullivan LE, Tetrault JM, et al. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94:38–47.
   PubMed Web of Science ®Google Scholar
• Americans' attitudes about prescription painkiller abuse. Harvard. TH Chan School of Public Health.  Available from: https://cdn1.sph.harvard.edu
   Google Scholar
• Franklin G, Sabel J, Jones CM, et al. A comprehensive approach to address the prescription opioid epidemic in Washington State: milestones and lessons learned. Am J Public Health. 2015;105:463–469.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Craig D, Giarratano. AUS Food and Drug Administration's Risk evaluation and mitigation strategy for extended-release and long-acting opioids: pros and cons, and an European perspective. Drugs. 2012 Dec 24;72(18):2327–2332.
   Google Scholar
• Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17:85–98.
   PubMed Web of Science ®Google Scholar
• Nicholas MK, Blyth FM. Are self-management strategies effective in chronic pain treatment? Pain Manag. 2016;6:75–88.
   PubMed Web of Science ®Google Scholar
• Kaye AD, Jones MR, Kaye AM, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain Physician. 2017;20(2S):S93–S109.
   PubMed Web of Science ®Google Scholar
• Lin DH, Lucas E, Murimi IB, et al. Financial conflicts of interest and the centers for disease control and prevention’s 2016 guideline for prescribing opioids for chronic pain. JAMA Intern Med. 2017;177:427–428.
   PubMed Web of Science ®Google Scholar
• Hurstak EE, Kushel M, Chang J, et al. The risks of opioid treatment: perspectives of primary care practitioners and patients from safetynet clinics. Subst Abus. 2017;38:213–221.
   PubMed Web of Science ®Google Scholar
• Harvard and Chan School of Public Health. American’s attitudes about prescription painkiller abuse. Opioids and Addiction. A Governors Roundtable on State Approaches to Treatment. Available from: https://www.hsph.harvard.edu/horp/stat-harvard-polls/
   Google Scholar
• Patrick SW, Fry CE, Jones TF, et al. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35:1324–1332.
   PubMed Web of Science ®Google Scholar
• Meara E, Horwitz JR, Powell W, et al. State legal restrictions and prescription- opioid use among disabled adults. N Engl J Med. 2016;375:44–53.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Zhang F, Ross-Degnan D, et al. Rates of opioid dispensing and overdose after introduction of abuse- deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175:978–987.
   PubMed Web of Science ®Google Scholar
• Sacarny A, Yokum D, Finkelstein A, et al. Medicare letters to curb overprescribing of controlled substances had no detectable effect on providers. Health Aff (Millwood). 2016;35:471–479.
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Xuan Z, Shanahan CW, et al. Improving adherence to long-term opioid therapy guidelines to reduce opioid misuse in primary care: a cluster-randomized clinical trial. JAMA Intern Med. 2017;177:1265–1272.
   PubMed Web of Science ®Google Scholar
• Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose. A cohort study. Ann Intern Med. 2010;152:85–92.
   PubMed Web of Science ®Google Scholar
• Zedler BK, Saunders WB, Joyce AR, et al. Validation of a screening risk index for serious prescription opioid induced respiratory depression or overdose in a US commercial health plan claims database. Pain Med. 2018;19:68–78.
   PubMed Web of Science ®Google Scholar
• Brown RE Jr, Sloan PA. The opioid crisis in the United States: chronic pain physicians are the answer, not the cause. Anesth Analg. 2017;125:1432–1434.
   PubMed Web of Science ®Google Scholar
• Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 versus DSM-4 diagnostic criteria. J Addict Dis. 2011;30:185–194.
   PubMed Web of Science ®Google Scholar
• Wasan AD, Michna E, Edwards RR, et al. Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology. 2015;123:861–872.
   PubMed Web of Science ®Google Scholar
• Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med. 2010;25:310–315.
   PubMed Web of Science ®Google Scholar
• Vuong C, Van Uum SH, O’Dell LE, et al. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31:98–132.
   PubMed Web of Science ®Google Scholar
• Edwards RR, Dolman AJ, Michna E, et al. Changes in pain sensitivity and pain modulation during oral opioid treatment: the impact of negative affect. Pain Med. 2016;17:1882–1891.
   PubMed Web of Science ®Google Scholar
• Rauck RL, Hong KJ, North J. Opioid-induced constipation survey in patients with chronic noncancer pain. Pain Pract. 2017;17:329–335.
   PubMed Web of Science ®Google Scholar
• Thomson MW, Poulton R, Broadbent MJ, et al. Xerostomia and medications among 32-year-olds. Acta Odontol Scand. 2006;64:249–254.
   PubMed Web of Science ®Google Scholar
• Kolodny A, Frieden TR. Ten steps the federal government should take now to reverse the opioid addiction epidemic. JAMA. 2017;318:1537–1538.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Whittington RA, et al. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008;33:1179–1191.
   PubMed Web of Science ®Google Scholar
• US FDA (Food Drug Admin.). 2012. Comment from physicians for responsible opioid prescribing on the Food and Drug Administration (FDA) notice: draft blueprint for prescriber education; availability: longacting/extended-release opioid class-wide risk evaluation and mitigation strategy. Phys. Responsib. Opioid Prescr. (PROP). FDA-FDA Petition 2012, Regulations.gov, Washington, DC. Available from: http://www.regulations.gov/#!documentDetail;D=FDA-2011-D-0771-0069
   Google Scholar
• Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205–217.
   PubMed Web of Science ®Google Scholar
• Jones CM, Paulozzi LJ, Mack KA. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use United States, 2008–2011. JAMA Intern Med. 2014;174:802–803.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Kim M, Nikitin RV, et al. Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts. Pharmacoepidemiol Drug Saf. 2014;23:950–957.
   PubMed Web of Science ®Google Scholar
• Kreiner P, Nikitin R, Shields TP Bureau of justice assistance prescription drug monitoring program performance measures report: January 2009 through June 2012. Waltham, MA: PDMP Cent. Excell., Brandeis Univ.
   Google Scholar
• Hopkins D, Dreyzehner JJ, O’Leary T. Lessons learned from mandating prescriber compliance. Presented at Natl. Prescr. Abuse Sum.; 2014 Apr 22–23; Atlanta.
   Google Scholar
• Reif S, George P, Braude L, et al. Residential treatment for individuals with substance use disorders: assessing the evidence Psychiatr. Serv. 2014;65:301–312.
   Google Scholar
• Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290–1297.
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662–668.
   PubMed Web of Science ®Google Scholar
• Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475–486.
   PubMed Web of Science ®Google Scholar
• Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance for opioid dependence. JAMA. 2000;284:694–695.
   PubMedGoogle Scholar
• Strain EC, Bigelow GE, Liebson IA, et al. Moderate versus high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000–1005.
   PubMed Web of Science ®Google Scholar
• Coyle MG, Salisbury AL, Lester BM, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012;107:63–73.
   PubMed Web of Science ®Google Scholar
• McCarthy JJ, Leamon MH, Parr MS, et al. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol. 2005;193:606–610.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Byrd-Sellers J, et al. Safety and efficacy of long-term buprenorphine maintenance treatment. Addict Dis Treat. 2011;10:123–130.
   Google Scholar
• Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95:1439–1444.
   PubMed Web of Science ®Google Scholar
• Digiusto E, Shakeshaft A, Ritter A, et al. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99:450–460.
   PubMed Web of Science ®Google Scholar
• Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82:303–311.
   PubMed Web of Science ®Google Scholar
• Williams AV, Marsden J, Strang J. Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. Addiction. 2014;109:250–259.
   PubMed Web of Science ®Google Scholar
• CDC(Cent. Dis. Control Prev.). Community-based opioid overdose prevention programs providing naloxone—United States, 2010. Mmwr. 2012;6:101–105.
   Google Scholar